Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.

• Status: Completed
• Trial end date: 2020-11-20
• Target enrollment: 0
• Participant gender: All

Summary

Burden:

Initial outbreak of corona virus disease 2019 (COVID-19) was reported from Wuhan, China in early December 2019.Presently known to be caused by a novel beta-corona virus, named as Severe acute respiratory syndrome corona virus 2 ( SARS-CoV-2).

World Health Organization (WHO) declared a pandemic on March.

The clinical characteristics of COVID-19 include respiratory symptoms, fever, cough, dyspnoea and pneumonia

Infected individuals exhibit:

1. Mostly mild illness (80% +) recover without any treatment (~80%)

2. Moderate illness that needs hospitalization and recovers after standard

3. supportive treatment (~14%)

4. Critical illness (~5%) needs ICU support

5. Death (1-2% )

COVID-19 has now spread >210 countries and territories globally. SARS-CoV-2 is a respiratory virus which spreads primarily through droplets generalized when an infected person coughs or sneezes or through droplets of saliva or discharge from the nose.

Symptomatic management remains the mainstay of treatment strategy. Mortality appears to be more common in older individuals and those with co-morbidities, such as chronic lung disease, cardiovascular disease and diabetes. Young people with no comorbidities also appear to be at risk for critical illness including multi-organ failure and death. Seen more in Bangladesh between 21-40 yrs of age.

Knowledge Gap:

There is no specific treatment against this new virus that WHO has officially declared until now.There are many pharmacologic therapies that are being used or considered for treatment of COVID-19. National Guidelines on Clinical Management of Corona virus Disease 2019 (Covid-19): V 5.0 date 9th April 2020) CDC, DGHS, GoB

Thus an RCT is urgently needed in Bangladesh: Based on recent literatures on Rx studies in COVID-19 patients from other countries as well as its availability & affordability of those repurposed medicines

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
• Treatments: Doxycycline; Ivermectin

Criteria

Inclusion criterion:

• Bangladeshi aged 18-65 years admitted to any of the aforementioned study sites (hospitals)

• Either sex

• At the enrollment having at least one of the following symptoms: Temp 37.5 C or above, Cough, Sore throat

• SpO2 >94%

• Duration of illness ≤ 7 days

• No oxygen support on enrollment

• Capable of swallowing oral medication

• PCR positive for SARS-CoV2 virus

• The participant properly informed about the study and agreed to sign the informed consent form (ICF)

Exclusion Criteria:

• Allergy to ivermectin or doxycycline; or other contraindications to any of the study medications

• History of chronic heart disease (IHD, heart failure, documented cardiomyopathy etc)

• History of chronic liver disease (SGPT value more than 3 times of normal value)

• History of chronic kidney disease (S. Creatinine for male >1.3 mg/dL or >115 µmol/L and for female >1.2 mg/dL or >106.1 µmol/L)

• Pregnant or lactating women

• Participated in any other clinical trial within last 4 weeks

• H/o received Ivermectin/Doxycycline within last 7 days